微小RNA在慢性丙型肝炎患者干扰素治疗反应中的作用
The Role of MicroRNAs in Response to Interferon Treatment of Chronic Hepatitis C patients.
作者信息
El-Ahwany Eman, Nagy Faten, Zoheiry Mona, ELGhannam Maged, Shemis Mohamed, Aboul-Ezz Mohamed, Zada Suher
机构信息
Immunology Department, Theodor Bilharz Research Institute, Giza, Egypt.
Hepato-gastroenterology Department, Theodor Bilharz Research Institute, Giza, Egypt.
出版信息
Electron Physician. 2016 Feb 25;8(2):1994-2000. doi: 10.19082/1994. eCollection 2016 Feb.
INTRODUCTION
Treatment of HCV using a combination of pegylated interferon (PEG-IFN) and ribavirin fails in about 40% of the patients with HCV genotype 4 infections, and it is physically and economically demanding. Thus, it is highly important to identify factors that can help to predict the likelihood that a patient will respond to this treatment.
METHODS
In this study, five miRNAs, i.e., miRNA-122, miRNA-199, miRNA-192, miRNA-30, and miRNA-128, were selected according to previous studies that demonstrated their noticeable functions in viral replication, indicating that they potentially could be used by host cells to control viral infections. The five miRNAs were measured using real-time, reverse transcription-polymerase chain reactions. The data were analyzed using the t-test and chi-squared test.
RESULTS
We found that the expression level of miRNA-122 was significantly increased in the responders' group (p < 0.01) over that in the non-responders' groups before and after treatment; both increased significantly (p < 0.01) compared with the normal control group.
CONCLUSION
miR-122 might be a useful predictor for virological responses to treatment with PEG-interferon plus ribavirin therapy in patients with HCV.
引言
使用聚乙二醇化干扰素（PEG-IFN）和利巴韦林联合治疗丙型肝炎病毒（HCV）时，约40%的HCV基因4型感染患者治疗失败，且该治疗对身体和经济要求较高。因此，识别有助于预测患者对该治疗反应可能性的因素非常重要。
方法
在本研究中，根据先前研究选择了5种微小RNA（miRNA），即miRNA-122、miRNA-199、miRNA-192、miRNA-30和miRNA-128，这些研究表明它们在病毒复制中具有显著功能，表明它们可能被宿主细胞用于控制病毒感染。使用实时逆转录聚合酶链反应测量这5种miRNA。使用t检验和卡方检验分析数据。
结果
我们发现，治疗前后，应答者组中miRNA-122的表达水平均显著高于无应答者组（p<0.01）；与正常对照组相比均显著升高（p<0.01）。
结论
miR-122可能是HCV患者接受PEG-干扰素加利巴韦林治疗病毒学反应的有用预测指标。
Zotero 插件